Search For Lab Tests Here

The Syphilis Test is an RPR Test with Reflex to Titer and Confirmatory Testing that screens for antibodies to Treponema pallidum. If reactive, additional testing confirms infection and measures antibody levels to assess disease activity. Doctors use this blood test to diagnose syphilis, determine stage, and monitor treatment response. It is widely used in STD screening, prenatal care, and early detection to prevent complications and transmission.

The Syphilis FTA-ABS Test (Fluorescent Treponemal Antibody Absorption) detects antibodies specific to Treponema pallidum, the bacteria that cause syphilis. Doctors use this confirmatory test after a positive screening to verify infection, even in late or latent stages. Results help distinguish syphilis from false positives, guiding diagnosis, treatment, and follow-up. This test is essential for accurate detection and long-term monitoring of syphilis.

The Syphilis RPR Test screens for syphilis by detecting nonspecific antibodies produced in response to Treponema pallidum. If positive, a reflex titer is performed to measure antibody levels and monitor disease activity. Doctors use this blood test to confirm infection, determine stage, and track treatment response. It is widely used for STD screening, prenatal care, and early detection to prevent complications and transmission.

The Syphilis (RPR + FTA-ABS) panel is a diagnostic tool used to detect and confirm the presence of syphilis, a sexually transmitted infection (STI) caused by the bacterium Treponema pallidum. This panel combines two tests: the RPR (Rapid Plasma Reagin) Screen with Reflex to Titer, and the FTA-ABS (Fluorescent Treponemal Antibody Absorption) test, offering both initial screening and confirmatory diagnosis capabilities.

Why pay $69 for Everlywell's Syphilis finger prick test kit when you can experience the convenience and affordablity of a Syphilis lab test with Ulta Lab Tests - compare now and save!

The RPR Test with Reflex to Titer and Confirmatory Testing screens for syphilis by detecting non-treponemal antibodies. If reactive, results are automatically followed by a titer to measure antibody concentration and confirmatory treponemal testing for accuracy. Doctors use this test to diagnose active or past syphilis, monitor treatment, or screen at-risk patients. Results provide vital insight into infection status, disease stage, and overall sexual health.

The RPR (Monitor) with Reflex to Titer Test screens for syphilis by detecting antibodies to Treponema pallidum. If positive, a reflex titer determines antibody concentration to assess disease activity and treatment response. Doctors order this test to diagnose syphilis, monitor therapy, or check reinfection. Results provide essential information for managing active infection, confirming treatment success, and guiding follow-up care.

The Sexual Health & STI Screening Advanced Male Lab Panel includes 8 tests and 39 biomarkers to support expanded STI screening for men. It evaluates chlamydia, gonorrhea, hepatitis B, hepatitis C, HSV-1, HSV-2, syphilis, and urine health. This panel includes molecular chlamydia/gonorrhea testing, hepatitis B markers, hepatitis C reflex testing, HSV IgG with reflex HSV-2 inhibition, RPR with reflex confirmation, and urinalysis.

 The STD Basic panel is a curated selection of tests aimed at detecting some of the most common sexually transmitted diseases (STDs). These tests employ various laboratory techniques to identify the presence of specific pathogens or the body's immune response to them. By providing insights into an individual's sexual health status, this panel plays a pivotal role in early detection, treatment, and prevention of further transmission of these infections.

 The STD Comprehensive panel offers a broad overview of an individual's sexual health by screening for several prevalent sexually transmitted diseases. This comprehensive approach ensures that both bacterial and viral infections are tested for, providing a detailed picture of potential risks and existing infections, many of which may be asymptomatic.

The Sexual Health & STI Screening Essential Lab Panel includes 3 tests and 5 biomarkers to support focused screening for common sexually transmitted infections, including chlamydia, gonorrhea, hepatitis C, and syphilis. It uses molecular testing for chlamydia and gonorrhea, hepatitis C antibody testing with reflex RNA confirmation when indicated, and RPR testing with reflex titer and confirmatory testing for syphilis screening support.

The Beta-2-Glycoprotein I IgA Antibody Test detects IgA antibodies targeting beta-2 glycoprotein I, helping identify autoimmune conditions and clotting disorders. Positive results may indicate antiphospholipid syndrome, thrombotic risk, or pregnancy complications. This test provides insight into immune activity, vascular health, and systemic conditions linked to abnormal coagulation and inflammation.

The Beta-2-Glycoprotein I IgG Antibody Test detects IgG antibodies targeting beta-2 glycoprotein I, helping assess autoimmune disorders and clotting risk. Positive results may indicate antiphospholipid syndrome, pregnancy complications, or thrombotic conditions. This test provides insight into vascular health, immune response, and systemic disorders related to antibody activity and coagulation balance.

The Beta-2-Glycoprotein I IgM Antibody Test detects IgM antibodies targeting beta-2 glycoprotein I to help assess autoimmune activity and clotting disorders. Positive findings may suggest antiphospholipid syndrome, thrombotic risk, or recurrent miscarriage. This test provides insight into vascular health, immune regulation, and systemic disorders tied to antibody activity and coagulation balance.

The Chlamydia trachomatis RNA TMA Urine Test detects genetic material of C. trachomatis using transcription-mediated amplification (TMA), a highly sensitive method for diagnosing infection. Doctors order this noninvasive urine test for patients with symptoms like discharge, pain, or burning urination, or for routine STD screening. Results help confirm infection, guide treatment, and prevent complications such as infertility, pelvic inflammatory disease, or transmission.

The Sexual Health & STI Screening Advanced Female Lab Panel includes 10 tests and 41 biomarkers to support expanded STI screening for women. It evaluates chlamydia, gonorrhea, trichomonas, hepatitis B, hepatitis C, HSV-1, HSV-2, syphilis, pregnancy status, and urine health. Includes molecular STI testing, hepatitis B markers, hepatitis C reflex RNA, HSV IgG with reflex HSV-2 inhibition, RPR with reflex confirmation, hCG, and urinalysis.

The Neisseria gonorrhoeae RNA TMA Urine Test detects gonorrhea infection by identifying bacterial RNA using transcription-mediated amplification. This highly sensitive urine test helps diagnose current gonorrhea infections, even in asymptomatic cases. Doctors use it for early detection, accurate diagnosis, and timely treatment to prevent complications. Results support effective STD management and help reduce the risk of transmission.

The Chlamydia/Neisseria gonorrhoeae RNA, TMA Urine Test screens for both chlamydia and gonorrhea infections by detecting RNA from these bacteria. Using advanced molecular technology, it offers high accuracy for diagnosing active infections. Doctors order this urine-based test to confirm infection, support early treatment, and protect sexual partners. It is an essential tool for sexual health screening, helping reduce long-term health risks and control STD spread.

The Herpes 1 and 2 Test uses type-specific HSV-1/HSV-2 IgG to assess past infection and differentiate exposure to each virus. It is useful for evaluating recurrent lesions, screening asymptomatic partners, and documenting baseline status for clinical management. Because IgG can take 2–12 weeks to develop, early negatives may need repeat testing; HSV-2 reactive results reflex to an inhibition assay to verify specificity and reduce cross-reactivity.

The Lyme Disease IgG IgM Antibodies Immunoblot Test detects antibodies to Borrelia burgdorferi, the bacteria causing Lyme disease. IgM indicates recent infection, while IgG suggests past or ongoing infection. Doctors order this test to confirm exposure after ELISA screening or when symptoms such as rash, fatigue, joint pain, or neurological issues appear. Results provide critical insight for diagnosing and managing Lyme disease with greater accuracy.